About Urovant Sciences
Urovant Sciences is a Biopharmaceutical company focused on developing and commercializing innovative therapies for a range of urologic conditions. The company estimated annual revenue is currently 39.2 million USD per year. The headquarters is in USA.
More about Urovant Sciences
- Acquisitions and changes
- No longer listed: ticker UROV is not in the SEC's, the US exchanges' or FINRA's lists of traded securities (checked 14 November 2026).
Market cap history
World rank over time
Rank in USA: #2,536 (Jan 2020) · #2,731 (Jan 2021)
Lobbying by Urovant Sciences#
$70 K spent on lobbying the US Congress and federal agencies in 2020, most often on health issues and budget/appropriations.
- Health Issues3 reports
- Budget/Appropriations1 report
Lobbying firms hired in 2020
Forbes-Tate $70 K
| Year | Spending | Own lobbyists | Reports |
|---|---|---|---|
| 2020 | $70 K | — | 3 |
Source: Lobbying Disclosure Act reports (Form LD-2). Filed as “Urovant Sciences”. Reports round to the nearest $10,000, and one of less than $5,000 counts as zero
H-1B hiring at Urovant Sciences#
1 labor condition applications certified in fiscal 2021 for 1 positions, at a median wage of $235 K a year.
| Job title | Positions | Median wage offered |
|---|---|---|
| Senior Director, Pricing, Contracts & AnalyticsMarketing Managers | 1 | $235 K |
Where: Irvine, CA 1
Source: US Department of Labor, LCA disclosure data. An application is not a visa: USCIS decides each petition later, and the yearly lottery limits new H-1B visas. Filed as Urovant Sciences, Inc
From US state WARN notices and SEC 8-K restructuring filings, newest first.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 | · | · | · | 22 | 1 | · | · | · | · | · | · | · | 23 |
| Announced | People | Kind | Where | Source |
|---|---|---|---|---|
| effective | 1 person | LayoffWARN notice | Irvine, California | Notice list |
| effective | 22 people | LayoffWARN notice | Irvine, California | Notice list |
Source: State WARN notices and SEC 8-K item 2.05
Peer comparison · Biotechnology
| Company | Market cap | P/E | Net margin | Rev. growth |
|---|---|---|---|---|
| Urovant Sciences🇺🇸 | $512 M | — | — | — |
| Novo Nordisk A/S🇩🇰 | $203.2 B | 13.1× | 33.1% | +10.8% |
| Vertex Pharmaceuticals Incorporated🇺🇸 | $134.3 B | 33.8× | 30.7% | +8.9% |
| Moderna, Inc.🇺🇸 | $90.1 B | — | -110.5% | -39.9% |
| Regeneron Pharmaceuticals, Inc.🇺🇸 | $84.1 B | 17.5× | 28.5% | +1.0% |
| Argenx SE🇳🇱 | $52.8 B | 40.9× | 31.1% | +89.9% |
| CSL Limited🇦🇺 | $51.6 B | — | -16.4% | — |
| Samsung Biologics Co., Ltd.🇰🇷 | $51.5 B | 40.5× | 39.2% | — |
| UCB SA🇧🇪 | $48.6 B | 26.3× | 20.1% | +31.1% |
P/E and margins use trailing 12-month results where available; growth is the latest fiscal year.
Questions, comparisons and similar companies#
Compare head to head
Similar companies by size and industry
- Novo Nordisk A/S$203.2 B
- Vertex Pharmaceuticals Incorporated$134.3 B
- Moderna, Inc.$90.1 B
- Regeneron Pharmaceuticals, Inc.$84.1 B
- Argenx SE$52.8 B
- CSL Limited$51.6 B
Sources and freshness
- Market cap:
- Jan 1, 2021 (last known)
- Profile updated:
- Nov 14, 2026
Figures from value.today research.
How each figure is collected: data sources and methodology. Market caps in US dollars unless you switch the currency.
Work at Urovant Sciences? Verify and update this profile — free
Show Urovant Sciences's ranking on your website Get the badge
The badge updates itself as the ranking changes.